Overview
Zn²⁺-Ivermectin is a next-generation antiviral MDC prototype aimed at enhancing therapeutic bioavailability and cellular transport. Zinc ions act as viral replication disruptors and immune enhancers, while ivermectin retains its broad-spectrum antiviral mechanism with improved delivery characteristics.
Mechanism of Action
- Zn²⁺ binds viral polymerase and entry proteins, impairing replication fidelity
- Ivermectin's nuclear transport inhibition is amplified by metal-ligand synergy
- Improved epithelial uptake and oral bioavailability
Key Properties
- Enhanced mucosal absorption
- Stability under gastric pH conditions
- Reduces inflammatory cytokine release
Application
Therapeutic Class: Antiviral
Suggested use in viral respiratory conditions, with possible use in pandemic preparedness kits and immunomodulatory regimens.
Antiviral
Enhanced Bioavailability
Development Stage
Preclinical Evaluation
Further Information
For MDC licensing options, digital compound twins, or in vitro data, contact our research team.
Contact Us